Expansion Opportunities Headlands Research is actively expanding its California footprint and has recently acquired CTRsites, signaling aggressive growth and potential for new site partnerships, study capacity increases, and expanded patient access in the Western US.

Strategic Partnerships Existing collaborations with Pfizer and ongoing multi-site network positioning suggest headlands is versed in pharma-sponsored trials and can leverage coordinated site networks to support sponsor-led programs, especially in neurology, psychiatry, and CNS disorders.

Acquisition Momentum Frequent acquisitions (PharmaSite Research, Clinical Research Professionals, AMCR Institute) indicate a consolidation strategy that may require integration services, cross-sell of services, and expanded capabilities to existing and new sponsors.

Therapy Focus Breadth A broad therapeutic area exposure across Allergy, Cardiology, Dermatology, Oncology, CNS, Infectious Disease, Pediatrics, and more positions Headlands to support diverse trial pipelines and help sponsors achieve trial diversity and faster site activation.

Size and Reach With 51-200 employees and a revenue range of 25–50 million, Headlands sits between boutique and mid-market CROs, offering a nimble yet capable platform for rapid startup, patient recruitment capabilities, and collaborative study management for mid-to-large phase trials.